Background Chronic anticoagulation with vitamin K antagonists (VKAs) is recommended in
patients with hypertrophic cardiomyopathy (HCM) and atrial fibrillation (AF). Direct oral …

Background Chronic anticoagulation is recommended in patients with hypertrophic
cardiomyopathy (HCM) and atrial fibrillation (AF). Non-vitamin K antagonist oral …

Hypertrophic cardiomyopathy (HCM) patients with nonvalvular atrial fibrillation (AF) have an
increased risk of suffering thromboembolic events. Vitamin K antagonists (VKA) are …

Several studies have explored the use of NOACs compared with vitamin K antagonists
(VKAs) in patients with hypertrophic cardiomyopathy (HCM) and atrial fibrillation (AF); and …

Background and Purpose—Hypertrophic cardiomyopathy patients with atrial fibrillation are
at increased risk of stroke, and anticoagulation is strongly recommended. However, limited …

Hypertrophic cardiomyopathy (HCM) affects> 600,000 patients in the United States, and
approximately 1 in 5 of them have atrial fibrillation (AF)(1). The incidence of stroke in …

Atrial fibrillation is the most common arrhythmia in patients with hypertrophic
cardiomyopathy, with a prevalence of 23% and incidence of 3.1%. The risk of …

Background Anticoagulation is recommended for hypertrophic cardiomyopathy (HCM) with
nonvalvular atrial fibrillation (NVAF) according to European and American guidelines …

Background There have been no prior nationwide reports on the prevalence of hypertrophic
cardiomyopathy (HCM) among patients suffering from atrial fibrillation (AF). It is also unclear …

Atrial fibrillation (AF) is the most common sustained arrhythmia in hypertrophic
cardiomyopathy (HCM) with clinical and subclinical episodes occurring in nearly one-half of …